AskAt Inc. (AskAt) received a Notice of Allowance dated November 3, 2020 from the United States Patent and Trademark Office (USPTO) in connection with Application No.16/803,163, a use patent for AskAt’s EP4 antagonist (grapiprant, AAT-007) in the treatment of melanoma, leukemia, lymphoma, and liver cancer. AskAt has previously received an allowance for the use of grapiprant in the treatment of epithelial cancer and several cancer types.

Ikena Oncology, Inc (formally Kyn Therapeutics, Inc. which licensed worldwide rights to AskAt’s EP4 antagonists except in China) and Ningbo NewBay Pharmaceutical Co. Ltd. (a subsidiary of Ningbo Tai Kang Medical Technology Co. Ltd., which licensed AskAt’s EP4 antagonists for cancer use in China) are currently conducting clinical studies of grapiprant (IK-007/RMX-1002) in the U.S. and China, respectively.